BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 28296257)

  • 1. Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome.
    Bowman SJ; Everett CC; O'Dwyer JL; Emery P; Pitzalis C; Ng WF; Pease CT; Price EJ; Sutcliffe N; Gendi NST; Hall FC; Ruddock SP; Fernandez C; Reynolds C; Hulme CT; Davies KA; Edwards CJ; Lanyon PC; Moots RJ; Roussou E; Giles IP; Sharples LD; Bombardieri M
    Arthritis Rheumatol; 2017 Jul; 69(7):1440-1450. PubMed ID: 28296257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.
    Cornec D; Devauchelle-Pensec V; Mariette X; Jousse-Joulin S; Berthelot JM; Perdriger A; Puéchal X; Le Guern V; Sibilia J; Gottenberg JE; Chiche L; Hachulla E; Yves Hatron P; Goeb V; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Saliou P; Pers JO; Seror R; Saraux A
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):528-535. PubMed ID: 27390310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy.
    Cornec D; Devauchelle-Pensec V; Mariette X; Jousse-Joulin S; Berthelot JM; Perdriger A; Puéchal X; Le Guern V; Sibilia J; Gottenberg JE; Chiche L; Hachulla E; Hatron PY; Goeb V; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Seror R; Pers JO; Meiners PM; Vissink A; Bootsma H; Nowak E; Saraux A
    Rheumatology (Oxford); 2015 Sep; 54(9):1699-708. PubMed ID: 25957440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial.
    Meijer JM; Meiners PM; Vissink A; Spijkervet FK; Abdulahad W; Kamminga N; Brouwer E; Kallenberg CG; Bootsma H
    Arthritis Rheum; 2010 Apr; 62(4):960-8. PubMed ID: 20131246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study.
    Mariette X; Seror R; Quartuccio L; Baron G; Salvin S; Fabris M; Desmoulins F; Nocturne G; Ravaud P; De Vita S
    Ann Rheum Dis; 2015 Mar; 74(3):526-31. PubMed ID: 24347569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brief Report: Ultrasonographic Assessment of Salivary Gland Response to Rituximab in Primary Sjögren's Syndrome.
    Jousse-Joulin S; Devauchelle-Pensec V; Cornec D; Marhadour T; Bressollette L; Gestin S; Pers JO; Nowak E; Saraux A
    Arthritis Rheumatol; 2015 Jun; 67(6):1623-8. PubMed ID: 25708147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial.
    Gottenberg JE; Ravaud P; Puéchal X; Le Guern V; Sibilia J; Goeb V; Larroche C; Dubost JJ; Rist S; Saraux A; Devauchelle-Pensec V; Morel J; Hayem G; Hatron P; Perdriger A; Sene D; Zarnitsky C; Batouche D; Furlan V; Benessiano J; Perrodeau E; Seror R; Mariette X
    JAMA; 2014 Jul; 312(3):249-58. PubMed ID: 25027140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjögren's syndrome.
    Khurshudian AV
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2003 Jan; 95(1):38-44. PubMed ID: 12539025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The TRACTISS protocol: a randomised double blind placebo controlled clinical trial of anti-B-cell therapy in patients with primary Sjögren's Syndrome.
    Brown S; Navarro Coy N; Pitzalis C; Emery P; Pavitt S; Gray J; Hulme C; Hall F; Busch R; Smith P; Dawson L; Bombardieri M; Wan-Fai N; Pease C; Price E; Sutcliffe N; Woods C; Ruddock S; Everett C; Reynolds C; Skinner E; Poveda-Gallego A; Rout J; Macleod I; Rauz S; Bowman S;
    BMC Musculoskelet Disord; 2014 Jan; 15():21. PubMed ID: 24438039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS).
    Mariette X; Ravaud P; Steinfeld S; Baron G; Goetz J; Hachulla E; Combe B; Puéchal X; Pennec Y; Sauvezie B; Perdriger A; Hayem G; Janin A; Sibilia J
    Arthritis Rheum; 2004 Apr; 50(4):1270-6. PubMed ID: 15077311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of total glucosides of peony in the treatment of primary Sjögren's syndrome: a multi-center, randomized, double-blinded, placebo-controlled clinical trial.
    Liu X; Li X; Li X; Li Z; Zhao D; Liu S; Zhang M; Zhang F; Zhu P; Chen J; Wei W; Lin B; Zhou Y; Chen J; Pang Y; Zhang L; Sun X; Yu Z; Jia Y; Wang J; Sun W; Chiu F; Pang L; Wang G
    Clin Rheumatol; 2019 Mar; 38(3):657-664. PubMed ID: 30280368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).
    Meiners PM; Vissink A; Kroese FG; Spijkervet FK; Smitt-Kamminga NS; Abdulahad WH; Bulthuis-Kuiper J; Brouwer E; Arends S; Bootsma H
    Ann Rheum Dis; 2014 Jul; 73(7):1393-6. PubMed ID: 24473674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physical fatigue characterises patient experience of primary Sjögren's syndrome.
    Arends S; Meiners PM; Moerman RV; Kroese FG; Brouwer E; Spijkervet FK; Vissink A; Bootsma H
    Clin Exp Rheumatol; 2017; 35(2):255-261. PubMed ID: 28032845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. World Workshop on Oral Medicine VII: Immunobiologics for salivary gland disease in Sjögren's syndrome: A systematic review.
    Gueiros LA; France K; Posey R; Mays JW; Carey B; Sollecito TP; Setterfield J; Woo SB; Culton D; Payne AS; Lodi G; Greenberg MS; De Rossi S
    Oral Dis; 2019 Jun; 25 Suppl 1(Suppl 1):102-110. PubMed ID: 31140693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study.
    Dass S; Bowman SJ; Vital EM; Ikeda K; Pease CT; Hamburger J; Richards A; Rauz S; Emery P
    Ann Rheum Dis; 2008 Nov; 67(11):1541-4. PubMed ID: 18276741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary Sjögren's syndrome in Moroccan patients: characteristics, fatigue and quality of life.
    Ibn Yacoub Y; Rostom S; Laatiris A; Hajjaj-Hassouni N
    Rheumatol Int; 2012 Sep; 32(9):2637-43. PubMed ID: 21786120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-Analysis of Treatment for Primary Sjögren's Syndrome.
    Chu LL; Cui K; Pope JE
    Arthritis Care Res (Hoboken); 2020 Jul; 72(7):1011-1021. PubMed ID: 31058469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab Effectiveness and Safety for Treating Primary Sjögren's Syndrome (pSS): Systematic Review and Meta-Analysis.
    Souza FB; Porfírio GJ; Andriolo BN; Albuquerque JV; Trevisani VF
    PLoS One; 2016; 11(3):e0150749. PubMed ID: 26998607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of Severe Fatigue Following Nuclease Therapy in Patients With Primary Sjögren's Syndrome: A Randomized Clinical Trial.
    Posada J; Valadkhan S; Burge D; Davies K; Tarn J; Casement J; Jobling K; Gallagher P; Wilson D; Barone F; Fisher BA; Ng WF
    Arthritis Rheumatol; 2021 Jan; 73(1):143-150. PubMed ID: 32798283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gammalinolenic acid treatment of fatigue associated with primary Sjögren's syndrome.
    Theander E; Horrobin DF; Jacobsson LT; Manthorpe R
    Scand J Rheumatol; 2002; 31(2):72-9. PubMed ID: 12109650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.